Director Jan De Witte of ResMed Inc filed a Form 4 on November 18, 2026, disclosing the sale of 429 shares of ResMed common stock on November 17, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Jan De Witte, identified in the filing as a director of ResMed Inc (NYSE:RMD).
  • Shares sold: 429 shares of ResMed common stock disposed of (transaction code S) on November 17, 2026.
  • Sale price: $237 per share, as reported in the filing.
  • Remaining holdings: 3,772 shares of ResMed common stock held directly following the transaction.
  • 10b5-1 plan: The transaction was conducted under a Rule 10b5-1 plan adopted August 19, 2026, according to the filing.

De Witte's November 2026 Share Sale Under Prescheduled Trading Plan

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 18, 2026, Jan De Witte, a director at ResMed Inc, sold 429 shares of ResMed common stock on November 17, 2026, at a price of $237 per share. The filing records the transaction as a disposal (code S) of directly held securities.

The filing notes that the sale was executed pursuant to a Rule 10b5-1 plan that De Witte adopted on August 19, 2026. Rule 10b5-1 plans allow corporate insiders to establish prescheduled instructions for buying or selling securities at a time when they are not in possession of material nonpublic information. The filing indicates the box confirming compliance with Rule 10b5-1(c) was checked.

Following the reported transaction, the filing states that De Witte directly holds 3,772 shares of ResMed common stock. No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Jan De Witte, director, and dated November 18, 2026.

What Was Disclosed

Jan De Witte, a ResMed director, disclosed the sale of 429 shares of ResMed common stock at $237 per share on November 17, 2026, under a Rule 10b5-1 plan adopted August 19, 2026, leaving him with 3,772 directly held shares.